

## Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK<sup>™</sup> is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at [OLINVYK.com](http://OLINVYK.com). The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

## Trevena, Inc. Announces Three OLINVYK<sup>™</sup> Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting

Oct 5 2020, 7:00 AM EDT

## Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

Sep 21 2020, 7:00 AM EDT

## Trevena, Inc. to Present at September Virtual Investor Conferences

Sep 2 2020, 7:00 AM EDT

## Stock Overview

|               |                 |  |
|---------------|-----------------|--|
| Symbol        | TRVN            | LifeSci Advisors, LLC  |
| Exchange      | Nasdaq          | Dan Ferry  |
| Market Cap    | 426.37m         | Managing Director  |
| Last Price    | \$2.78          | T: 617-430-7576  |
| 52-Week Range | \$0.46 - \$3.68 | <a href="mailto:daniel@lifesciadvisors.com">daniel@lifesciadvisors.com</a> |

10/20/2020 04:00 PM EDT

## Investor Relations

## Management Team

### Carrie L. Bourdow

President and Chief Executive Officer

### Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary

### Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

### Barry Shin

Senior Vice President, Chief Financial Officer

### Robert T. Yoder

Senior Vice President, Chief Commercial Officer

### Joel S. Solomon, Esq.

Vice President, Legal & Compliance

### Linda Wase, MD

Vice President, Clinical Operations and Medical Affairs

### Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

### Katrine Sutton

Vice President, Finance Planning & Analysis

### Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

## Trevena, Inc.

955 Chesterbrook Blvd  
Suite 110  
Chesterbrook, PA 19087

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.